| 摘要 |
PROBLEM TO BE SOLVED: To provide solid pharmaceutical combinations for oral administration, comprising nicotinic acid or a nicotinic acid compound or mixtures thereof in a sustained release form and an HMG-CoA reductase inhibitor, which are useful for altering lipid levels in subjects suffering from, for example, hyperlipidemia and atherosclerosis, without causing drug-induced hepatotoxicity, myopathy or rhabdomyolysis. SOLUTION: Provided is a pharmaceutical composition to alter lipids in an individual without causing drug-induced hepatotoxicity, myopathy or rhabdomyolysis, wherein the pharmaceutical composition contains a solid oral dosage form for once per day single dose, the dosage form contains from about 250 mg to about 3,000 mg sustained release form nicotinic acid and from about 0.1 mg to about 80 mg immediate-release statin, and after the pharmaceutical composition is ingested by an individual, almost 100% of the nicotinic acid is released in blood flow within about 4 to about 8 hr. COPYRIGHT: (C)2010,JPO&INPIT
|
